Class Action

Aspercreme Pain Relief Patch

Class Action

Aspercreme Pain Relief Patch

Case Name (Date)

Cruz et al v. Sanofi US Corp.
21-cv-5536, N.D. Cal.
(May 2021)


Aspercreme Pain Relief Patch


Making misleading pain relief claims

Misleadingly marketing the product as “Max Strength” when other products deliver more lidocaine and are more effective

Misleadingly marketing the patch as “fast acting” when it does not provide immediate pain relief

Falsely claim that the product provides 12 hours of relief when the patch does not stay on for even six hours

Falsely marketing the product as compliant with FDA regulations when it is not



The Latest



Ad Alert

Aspercreme investigates after doctor challenges pain reliever’s “clinically proven” labeling claim on Twitter.